Immunocore’s upsized initial public offering in NASDAQ of 9,935,896 American Depositary Shares (“ADSs”) representing 9,935,896 ordinary shares at an initial public offering price of $26.00 per ADS, for total gross proceeds of approximately $258 million. The first day’s closing price jumps 66.15% to $43.2 per ADS, which represents a market cap of $1.796B.
Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX - Immune mobilizing monoclonal TCRs Against X disease - designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Immunocore's most advanced oncology therapeutic candidate, tebentafusp, demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma.
Read more ›